On Wednesday, June 20th, FDA announced the availability of a draft guidance entitled "Prescription Drug User Fee Waivers, Reductions, and Refunds for Drug and Biological Products." The guidance is an updated version of the original final guidance, which was published in September 2011.
Under section 736(d) of the Food, Drug, and Cosmetic (FD&C) Act, there are three main instances where the FDA will grant applicants a waiver or reduction in user fees. These include situations where:
According to section 736(i) of the FD&C Act, “to qualify for a waiver or reduction in user fees as well as a refund for a fee paid, an applicant must submit to FDA a written request for a user fee waiver, reduction or refund no later than 180 calendar days after the fee is due.” It is important to note that human drug applications without user fees are considered incomplete, and will not be accepted by FDA for filing, even if a sponsor’s failure to pay is due to waiver or reduction delays. As such, FDA suggests that applicants should submit requests for waivers or reductions three to four months before the submission of the application.
If FDA denies or partially denies a request, it is possible to submit a reconsideration request. Reconsideration requests must be made within 30 calendar days of the original FDA decision. Applicants should include any relevant updated financial information when submitting the request.
Upon reconsideration, a request may be granted or denied. If the request is denied, the applicant can appeal the denial. Appeal requests should be made within 30 calendar days of the decision to uphold the denial. Included in the appeal should be:
However, it is important to note that no new information should be included in the appeal request.
Public comment for this updated draft guidance will be open for 60 days following the publication of the Federal Register notice.
Are you in the process of preparing a human drug application for submission to the FDA? You could be eligible for a user fee waiver or reduction. We can help prepare and submit your application and determine whether you are a candidate for a waiver or reduction. To learn more about our services and how we can help you, contact us today.
October 27, 2015
On October 26, 2015, FDA released two draft guidances with interim regulations regarding the use of bulk drug substances in compounding under sections 503A and 503B of the Federal Food, Drug, and...
September 30, 2015
Currently, there are no regulations specifically regarding investigational tobacco products. As such, at this time they are not exempt from requirements stated in the FD&C Act. Last week, FDA...
September 15, 2015
In February 2000, FDA released a draft guidance entitled “Formal Dispute Resolution: Appeals Above the Division Level” which established procedures for resolving scientific and procedural disputes...